The National Cancer Institute's (NCI) Clinical Trials Cooperative Group Program has played a key role in developing new and improved cancer therapies. However, the program is falling short of its potential, and the IOM recommends changes that aim to transform the Cooperative Group Program into a dynamic system that efficiently responds to emerging scientific knowledge; involves broad cooperation of stakeholders; and leverages evolving technologies to provide high-quality, practice-changing research.

Table of Contents


Front Matter
Executive Summary
Overview of Conclusions and Recommendations
1 Introduction
2 The Science of Developing Cancer Therapy
3 Operations, Oversight, and Funding of Cancer Clinical Trials
4 Physician and Patient Participation in Cancer Clinical Trials
Appendix A: Previous and Ongoing Analyses Undertaken by NCI
Appendix B: Committee Member and Staff Biographies
Acronyms
Glossary